Eli Lilly (LLY)
(Real Time Quote from BATS)
$886.47 USD
+0.92 (0.10%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $886.00 -0.47 (-0.05%) 4:16 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$886.47 USD
+0.92 (0.10%)
Updated Oct 4, 2024 03:55 PM ET
After-Market: $886.00 -0.47 (-0.05%) 4:16 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.
Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.
Should You Buy Eli Lilly and Company (LLY) Ahead of Earnings?
by Zacks Equity Research
Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Teladoc Health's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.
Radius (RDUS) Up On Positive Data From Breast Cancer Study
by Zacks Equity Research
Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.
Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA
by Zacks Equity Research
United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib
by Zacks Equity Research
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $237.88 in the latest trading session, marking a +0.5% move from the prior day.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQL
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD
by Zacks Equity Research
Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.
Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations
by Zacks Equity Research
Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.
Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study
by Zacks Equity Research
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
AstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug
by Zacks Equity Research
If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.
Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More
by Kinjel Shah
Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.
The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp